Intranasal corticosteroids: do they improve ocular allergy?

Area of Science:

• Ophthalmology
• Allergology
• Pharmacology

Background:

• Allergic rhinoconjunctivitis (ARC) significantly impacts quality of life and incurs substantial healthcare costs.
• Current treatments for ARC include oral, ophthalmic, and intranasal medications.
• Intranasal corticosteroids (INS) are primary treatments for nasal symptoms but also affect ocular symptoms.

Purpose of the Study:

• To evaluate the efficacy of intranasal corticosteroids (INS) in managing ocular symptoms of allergic rhinoconjunctivitis (ARC).
• To explore the mechanism by which INS influence ocular symptom reduction.
• To emphasize the importance of study design in detecting ocular symptom changes in clinical trials.

Main Methods:

• Review of clinical trial data focusing on ocular symptom assessment in allergic rhinoconjunctivitis (ARC) patients using intranasal corticosteroids (INS).
• Analysis of study design elements, including the method and timing of ocular symptom scoring.
• Consideration of the proposed naso-ocular reflex pathway for INS action on the eyes.

Main Results:

• Intranasal corticosteroids (INS) demonstrate a significant impact on reducing ocular symptoms such as itching, tearing, and redness associated with allergic rhinoconjunctivitis (ARC).
• The observed effect of INS on ocular symptoms appears to be a class effect, consistent across different formulations.
• Study design, particularly the methodology and timing of ocular symptom evaluation, is critical for demonstrating the benefits of INS on eye symptoms.

Conclusions:

• Intranasal corticosteroids (INS) are effective in alleviating ocular symptoms in patients with allergic rhinoconjunctivitis (ARC).
• The naso-ocular reflex is a likely mechanism mediating the ocular benefits of INS.
• Optimized clinical trial designs are essential for accurately assessing the full therapeutic potential of INS in allergic rhinoconjunctivitis.